Among 13 analysts covering Heron Therapeutics (NASDAQ:HRTX), 13 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Heron Therapeutics has $58 highest and $22 lowest target. $37.18’s average target is 100.43% above currents $18.55 stock price. Heron Therapeutics had 29 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of Heron Therapeutics, Inc. (NASDAQ:HRTX) has “Buy” rating given on Wednesday, December 6 by Cowen & Co. Bank of America initiated the shares of HRTX in report on Wednesday, September 2 with “Buy” rating. The rating was maintained by Noble Financial on Friday, November 10 with “Buy”. The firm has “Buy” rating given on Monday, August 3 by Brean Capital. Cowen & Co maintained Heron Therapeutics, Inc. (NASDAQ:HRTX) rating on Monday, November 6. Cowen & Co has “Buy” rating and $40.0 target. Leerink Swann maintained Heron Therapeutics, Inc. (NASDAQ:HRTX) on Wednesday, September 23 with “Outperform” rating. Aegis Capital maintained it with “Buy” rating and $3300 target in Thursday, June 1 report. As per Friday, November 10, the company rating was maintained by Oppenheimer. Cowen & Co maintained Heron Therapeutics, Inc. (NASDAQ:HRTX) rating on Thursday, August 3. Cowen & Co has “Buy” rating and $4000 target. The rating was maintained by Cantor Fitzgerald on Friday, August 18 with “Buy”.
Dhi Group Incorporated (NYSE:DHX) had an increase of 7.05% in short interest. DHX’s SI was 2.05M shares in January as released by FINRA. Its up 7.05% from 1.91 million shares previously. With 260,600 avg volume, 8 days are for Dhi Group Incorporated (NYSE:DHX)’s short sellers to cover DHX’s short positions. The stock decreased 5.13% or $0.1 during the last trading session, reaching $1.85. About 154,851 shares traded. DHI Group, Inc. (NYSE:DHX) has declined 58.64% since January 6, 2017 and is downtrending. It has underperformed by 75.34% the S&P500.
Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company has market cap of $1.19 billion. The companyÂ’s product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single subcutaneous injection. It currently has negative earnings. It offers SUSTOL extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens.
Analysts await Heron Therapeutics, Inc. (NASDAQ:HRTX) to report earnings on February, 22. They expect $-0.82 EPS, up 32.79% or $0.40 from last year’s $-1.22 per share. After $-0.77 actual EPS reported by Heron Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 6.49% negative EPS growth.
It closed at $18.55 lastly. It is down 20.92% since January 6, 2017 and is downtrending. It has underperformed by 37.62% the S&P500.
DHI Group, Inc. provides specialized Websites focused on select professional communities in the United States and internationally. The company has market cap of $92.95 million. It operates through three divisions: Tech & Clearance, Global Industry Group, and Healthcare. It has a 9.16 P/E ratio. The firm operates Dice that provides job postings of technology and non-technology companies for industries, such as positions for software engineers, big data professionals, systems administrators, database specialists, project managers, and other technology and engineering professionals; and ClearanceJobs, an Internet career network that matches security-cleared professionals with hiring companies searching for employees.
Among 4 analysts covering Dice Holdings (NYSE:DHX), 1 have Buy rating, 1 Sell and 2 Hold. Therefore 25% are positive. Dice Holdings had 6 analyst reports since August 31, 2015 according to SRatingsIntel. The firm has “Mkt Outperform” rating given on Wednesday, December 2 by Avondale. The firm has “Sell” rating given on Monday, September 7 by Zacks. On Monday, August 31 the stock rating was upgraded by Zacks to “Sell”.